MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025

MIMEDX GROUP, INC.

2024-FY EPS reported $0.28 revenue$348,879,000

Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.
GAAP net income Q4 $7M ($0.05 EPS); full year $42M. Cash $104M at Dec 31, net cash $86M.
2025 outlook: net sales growth at least high single-digits, Adjusted EBITDA margin above 20%.
SG&A increased to $61M in Q4 from $54M a year ago; CEO cites Medicare disruption but remains confident.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.